Women’s Health: Legal and Commercial Considerations for Companies, Investors, and Strategic Partners

For years, the women’s health sector has been defined by underinvestment, diagnostic delay, insufficient clinical evidence, and fragmented patient data. Today, key stakeholders, from clinicians to regulators, are converging around a more commercially viable but legally complex women’s health innovation ecosystem.

Companies developing drugs, diagnostics, devices, digital health tools, and AI-enabled products for women’s health will need to navigate evolving expectations around clinical trial diversity, patient-centered endpoints, real-world evidence, privacy, reimbursement, regulatory engagement, and market access. Investors and strategic partners will also need to conduct due diligence to determine whether assets are supported by robust evidence and credible regulatory pathways, with commercially and clinically meaningful endpoints.  For developer and investor in-house legal teams, the challenge is to help the business move quickly without underestimating the regulatory, evidentiary, and transactional complexity of the sector.

The Morgan Lewis life sciences team explored these themes at Weatherden’s Women’s Health symposium.  The central message was clear: women’s health innovation must be approached as a rigorous, evidence-driven, commercially scalable sector requiring sophisticated regulatory and transactional strategies.

This Insight summarizes key discussions at the event and highlights areas where companies looking to expand into this space may want to focus resources to address some of the historical issues.

THE CONFERENCE’S KEY THEMES

Clinical Evidence in Women’s Health Is a Regulatory and Commercial Imperative

Data gaps remain one of the most significant barriers to women’s health innovation, with women continuing to be underrepresented in clinical trials and post-market evidence generation. This has resulted in cases of inadequate dosing information, restrictive product labeling, off-label prescribing, and delayed access.

This matters because regulators, investors, and strategic acquirers are increasingly focused on whether clinical evidence reflects the populations that will actually use the product and whether the product will be clinically meaningful for patients.  Trial designs that fail to account for sex, pregnancy status, hormonal cycles, life stage, ethnicity, and disease heterogeneity may face regulatory questions, reimbursement barriers, and diminished commercial credibility.

Practical considerations for companies and investors:

Companies should consider early engagement with regulators on inclusion criteria, benefit-risk framing, endpoint selection, and evidence generation plans. Legal and regulatory teams can assist with developing regulatory strategies for innovative products where there are limited market precedents.  In addition, clinical trial diversity and the quality of women-specific data should become core diligence items. Robust sex-disaggregated evidence and thoughtful inclusion strategies may improve asset value and reduce downstream regulatory risk.

Patient-Centered Endpoints Are Moving From ‘Nice to Have’ to Value-Critical

The speakers highlighted a recurring problem in women’s health: traditional endpoints often fail to capture what matters most to patients. For example, endometriosis, menopause, polyendocrine metabolic ovarian syndrome (PMOS), and fertility and pregnancy-associated conditions may involve a wide range of subjective symptoms that are inherently difficult to quantify. Factors such as pain, fatigue, sleep disruption, and mental health effects are important life-impacting symptoms for patients, but are difficult to record or measure, relying heavily on patient reported outcomes.

However, many outcome scales may not have been developed and may not be applicable in these indications.  As a result, clinical development programs often depend on endpoints that do not adequately reflect these experiences and are not intended for the relevant condition, which may have legal and commercial implications.

Regulators may require scientifically validated endpoints; however, other clinical factors will impact adoption and reimbursement and so both should be considered; a biomarker or surrogate endpoint may not be enough if it is not linked to meaningful clinical benefit for patients.  Similarly, patient-reported outcomes must be credible, validated, and integrated into a broader evidence package if they are to be accepted for regulatory approval.

Practical considerations for companies and investors:

Patient-centered endpoints and quality-of-life measures, such as fertility-related outcomes, sleep, pain, and disease burden, are likely to become increasingly important in both regulatory and reimbursement discussions. Regulators and investors are also likely to place greater pressure on companies to justify clinical trial populations and demonstrate that evidence reflects disease prevalence and real-world use. Companies should consider involving patients early in trial design, endpoint development, consent processes, recruitment strategies, and post-market evidence plans. However, legal and regulatory teams may need to help ensure that patient engagement is structured in a compliant way.

Diagnostics, Biomarkers, and Disease Subtyping Are Central to the Next Wave of Women’s Health Investment

A major theme at the symposium was the need to move beyond broad, one-size-fits-all disease categories. Endometriosis, PMOS, menopause-related symptoms, and other women’s health conditions are heterogeneous. Speakers drew comparisons to oncology, where subtyping and biomarker-driven development transformed treatment pathways and investment models.

For companies, the opportunity lies in building products that can better define patient populations, identify disease subtypes, and support targeted intervention. Diagnostics, imaging tools, biomarkers, and AI-enabled analytics may be especially important for biomarker-driven patient stratification. However, these products must be built on representative, high-quality datasets with biologically meaningful assumptions; AI trained on incomplete or male-skewed datasets may reproduce existing bias and create safety, regulatory, and product liability concerns.

Practical considerations for companies and investors:

AI-enabled diagnostics and digital biomarkers will attract investment, but only where companies can demonstrate representative datasets, clinical validity, regulatory strategy, and privacy-compliant data governance. The key diligence question is whether a diagnostic or biomarker strategy truly reduces development risk. Does it identify a clinically meaningful subgroup?  Does it support regulatory endpoints?  Is the research/discovery phase set up to identify markers that could become credible endpoints? Can it improve trial success, reimbursement, or adoption?  Is the data sufficiently representative and interoperable?  These questions should be addressed early in financing, collaboration, licensing, and M&A processes.

Real-World Evidence Has Strategic Value, but It Is Not a Substitute for Rigorous Development

Speakers emphasized the importance of real-world evidence, registries, longitudinal cohorts, imaging repositories, symptom tracking, and patient-generated data. These tools may help fill historic evidence gaps, support label expansion, improve patient stratification, and demonstrate value.  These data sets are underutilized, but caution is needed—they are often not combined or even compatible to enable combination, and speakers cautioned against overreliance on real-world evidence where the clinical data is weak.

Practical considerations for companies and investors:

The collection of real-world data must address privacy, cybersecurity, consent, data governance, interoperability, cross-border data transfers, secondary use, and AI training issues. It is also necessary to consider whether data collection tools are regulated as medical devices, whether digital endpoints require validation and are gathering genuinely helpful data, and whether patient-facing claims could create promotional or consumer protection risk.

Women’s Health Is More Investable, but Transaction Readiness Matters

The speakers also reflected on the shift in investor and pharma interest. Women’s health is increasingly viewed as a credible commercial opportunity, not merely an underfunded niche.  Large strategic transactions, renewed interest from pharmaceutical companies, and growing recognition of unmet need are changing the market.

However, transaction readiness remains critical. Investors and acquirers will look closely at clinical data quality, intellectual property (IP) protection, regulatory pathways, reimbursement assumptions, privacy and data rights, patient engagement practices, and scalability. Virtual operating models may offer efficiency and clean exit potential, but they also require careful contracting, governance, oversight, quality systems, and diligence preparation.

Practical considerations for companies and investors:

Collaborations among regulators, patient organizations, investors, clinicians, and industry will become increasingly important to support meaningful market adoption. The legal foundation should be built early.  Collaboration agreements, contract research organization  and vendor contracts, data rights, IP ownership, regulatory records, patient consents, and quality documentation can significantly affect financing and exit opportunities.

ACTION ITEMS FOR ORGANIZATIONS

Companies, investors, and strategic partners may want to consider the following steps to help drive these trends forward:

• Assess whether clinical development plans adequately include women across relevant stages, including pregnancy, breastfeeding, menopause, and reproductive age where appropriate.
• Engage regulators early on inclusion criteria, endpoints, benefit-risk framing, real-world evidence, and label strategy.
• Build patient input into trial design, endpoint development, recruitment, retention, and post-market evidence generation.
• Evaluate whether biomarkers, imaging tools, AI models, or digital endpoints are scientifically valid, representative, and capable of supporting regulatory and reimbursement objectives.
• Integrate reimbursement and market access planning into development strategy, rather than treating it as a post-approval issue.
• For investors and acquirers, include women-specific clinical evidence, endpoint credibility, regulatory strategy, data rights, and reimbursement assumptions into diligence.
• For emerging companies, prepare early for financing, partnering, or exit by maintaining clean documentation around IP, contracts, regulatory interactions, quality systems, and clinical data.

Building a Legal Foundation for Growth

Women’s health innovation sits at the intersection of life sciences regulation, clinical research, digital health, privacy, reimbursement, investment, and strategic transactions.  Counsel can help organizations move from scientific promise to commercial execution by aligning legal strategy with development, financing, and market access goals.

The companies that succeed in women’s health will be those that treat legal strategy as part of the innovation model, not as a downstream compliance check.  For in-house counsel, the opportunity is to help convert scientific promise into investable, scalable, and compliant execution.